Probiotics regulate the expression of COX-2 in intestinal epithelial cells

Nutrition and Cancer

Volumn 61, Issue 1, 2009, Pages 103-113

  Otte, Jan Michel ^a   Mahjurian Namari, Rudja ^a   Brand, Stephan ^b   Werner, Ilka ^a   Schmidt, Wolfgang E ^a   Schmitz, Frank ^a,c  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Klinikum Hildesheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CYCLOOXYGENASE 2; DEOXYRIBONUCLEASE; GASTRIN; PROBIOTIC AGENT; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL STRAIN COLO320; CELL STRAIN SW480; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HEAT; HOMEOSTASIS; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; LACTOBACILLUS ACIDOPHILUS; NONHUMAN; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SUPERNATANT; WESTERN BLOTTING; WOUND HEALING;

CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; EPITHELIAL CELLS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LACTOBACILLUS ACIDOPHILUS; LIGANDS; PROBIOTICS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TOLL-LIKE RECEPTORS;

BACTERIA (MICROORGANISMS); LACTOBACILLUS ACIDOPHILUS;

EID: 58149161378     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802372625     Document Type: Article

References (47)

1. Eaden JA, Abrams KR, and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535, 2001.
2. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(2 Suppl), 1-5, 2003.
3. Weitzman SA and Gordon LI: Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76, 655-663, 1990.
4. Gupta RA and DuBois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1, 11-21, 2001.
5. Kawai N, Tsujii M, and Tsuji S: Cyclooxygenases and colon cancer. Prostaglandins Other Lipid Mediat 187, 19668-19669, 2002.
6. Ristimaki A, Honkanen N, Jankala H, Sipponen P, and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57, 1276-1280, 1997.
7. Brown JR and DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10(12 Pt 2), 4266s-4269s, 2004.
8. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, et al.: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276, 18563-18569, 2001.
9. Marnett LJ and DuBois RN: COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42, 55-80, 2002.
10. Thun MJ, Namboodiri MM, and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325, 1593-1596, 1991.
11. Reddy BS, Tokumo K, Kulkarni N, Aligia C, and Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13, 1019-1023, 1992.
12. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, et al.: Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56, 710-714, 1996.
13. Ramsay RG, D Ciznadija, M Vanevski, and T Mantamadiotis: Transcriptional regulation of cyclooxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 16, 59-67, 2003.
14. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, and Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90, 11693-11697, 1993.
15. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, et al.: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91, 2046-2450, 1994.
16. Guo YS, Hellmich MR, Wen XD, and Townsend CM Jr: Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J Biol Chem276, 22941-22947, 2001.
17. Tessner TG, Muhale F, Schloemann S, Cohn SM, Morrison A, et al.: Basic fibroblast growth factor up-regulates cyclooxygenase-2 in 1407 cells through p38 MAP kinase. Am J Physiol 284, G269-G279, 2002.
18. Wollowski I, Rechkemmer G, and Pool-Zobel BL: Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73, 451-455, 2001.
19. Reddy BS and Riverson A: Inhibitory effect of Bifidobacterium longum on colon, mammary and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5- f]quinoline, a food mutagen. Cancer Res 53, 3914-3918, 1993.
20. Goldin BR and Gorbach SL: Effect of Lactobacillus acidophilus dietary supplements on 1,2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. J Natl Cancer Inst 64, 263-265, 1980.
21. Mitchell JA, Larkin S, and Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 50, 1535-1542, 1995.
22. Wallace JL: Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am 30, 971-980, 2001.
23. Tanabe T and Tohnai N: COX isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69, 95-114, 2002.
24. Hinz B and Brune K: Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 300, 367-375, 2002.
25. Jobin C, Morteau O, Han DS, and Balfour Sartor R: Specific NF-kappaB blockade selectively inhibits tumor necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 95, 537-543, 1998.
26. Weaver SA, Russo MP, Wright KL, Kolios G, Jobin C, et al.: Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. Gastroenterology 120, 1117-1127, 2001.
27. Guo YS, Cheng JZ, Jin GF, Gutkind JS, Hellmich MR, et al.: Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways: evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem 277, 48755-48763, 2002.
28. Colucci R, Blandizzi C, Tanini M, Vassalle C, Breschi MC, et al.: Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br J Pharmacol 144, 338-348, 2005.
29. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, et al.: Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 97, 1182-1186, 2002.
30. Otte JM and Podolsky DK: Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286, G613-G626, 2004.
31. Komori M, Tsuji S, Sun WH, Tsujii M, Kawai N, et al.: Gastrin enhances gastric mucosal integrity through cyclooxygenase-2 upregulation in rats. Am J Physiol Gastrointest Liver Physiol 283, G1368-G1378, 2002.
32. Tsuji S, Sun WH, Tsujii M, Kawai N, Kimura A, et al.: Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats. J Pharmacol Exp Ther 303, 1301-1308, 2002.
33. Yao M, Song DH, Rana B, and Wolfe MM: COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer. Br J Cancer 87, 574-579, 2002.
34. Whittle BJ: Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17, 301-313, 2003.
35. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623, 2004.
36. Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, et al.: Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140, 417-426, 2005.
37. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, et al.: Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132, 562-575, 2007.
38. Chapman TM, Plosker GL, and Figgitt DP: Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. BioDrugs 21, 61-63, 2007.
39. Nurmi JT, Puolakkainen PA, and Rautonen NE: Bifidobacterium Lactis sp. 420 up-regulates cyclooxygenase (Cox)-1 and down-regulates Cox-2 gene expression in a Caco-2 cell culture model. Nutr Cancer 51, 83-92, 2005.
40. Brzozowski T, Konturek PC, Mierzwa M, Drozdowicz D, Bielanski W, et al.: Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 11, 10-20, 2006.
41. Peran L, Camuesco D, Comalada M, Bailon E, Henriksson A, et al.: A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 103, 836-844, 2007.
42. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, et al.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520-528, 2004.
43. Obermeier F, Strauch UG, Dunger N, Grunwald N, Rath HC, et al.: In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 54, 1428-1436, 2005.
44. Cario E, Gerken G, and Podolsky DK: Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132, 1359-1374, 2007.
45. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, et al.: Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131, 862-877, 2006.
46. Yeo SJ, Gravis D, Yoon JG; and Yi AK: Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. J Biol Chem 278, 22563-22573, 2003.
47. Suzuki M, Hisamatsu T, and Podolsky DK: Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 71, 3503-3511, 2003.